ACRS.US Aclaris Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
3.91 USD
Close of Nov 13, 2026
2.34 6.60
Market cap
USD 620M
P/E
-
P/B
3.81x
ROE
-47.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ACRS.US undervalued?

Graham number

The Graham number of Aclaris Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aclaris Therapeutics Inc fundamental analysis

No fundamental analysis for Aclaris Therapeutics Inc yet.

Aclaris Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pul…

Full company profile